ALKS: Proprietary sales rose 31% as six orexin study readouts approach

What happened

Alkermes said its proprietary sales rose 31% year over year to $417.3 million in the third quarter, and adjusted EBITDA was $120.1 million. The company said this commercial strength supports investment in an orexin pipeline with six expected study readouts over the coming year.

Confirmed

Global impact / market context

Higher sales give Alkermes more cash to fund research without relying as heavily on outside financing. Six study results in one year create a steady stream of news that could change how investors value the orexin program and the whole company.

Analyst inference

Investors are weighing steady growth in the existing commercial business against the cost and uncertainty of the orexin research pipeline. The sales figure shows the base business is expanding, but upcoming study results will likely shape expectations for future revenue and spending.

Analyst inference

What to watch

1. Watch the six expected orexin study readouts over the coming year, since each result could change expectations for the pipeline's future value. Confirmed
2. Track whether Alkermes keeps increasing spending on the orexin program, which would affect costs and cash available for other uses. Proposed
3. Monitor whether proprietary sales growth continues at a similar pace, because slower growth could reduce the cash that funds research. Analyst inference

Evidence

• Original source link unavailable